Migenix initiates phase II trial of hepatitis C treatment (Hep C Chronic Fatigue)

Migenix initiates phase II trial of hepatitis C treatment
Datamonitor - With the large market potential and unmet need in current hepatitis C treatment, Celgosivir is an important component of our value proposition in the short-term. first-in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus infections

Patients with Hepatitis C using more healthcare resources
EurekAlert! - Hepatology is available online via Wiley InterScience Chronic Hepatitis C virus (HCV) affects about 3 million people

Positive phase I trial for Schering-Plough HCV treatment
Datamonitor - Currently, there are no products approved for treating HCV patients who failed previous therapies, representing an area of great unmet medical need. representing an area of great unmet medical need. Chronic hepatitis C affects more than 10 million people in major world